Transcode Therapeutics Stock Market Value
| RNAZ Stock | USD 9.49 0.99 9.45% |
| Symbol | Transcode |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Transcode Therapeutics. Anticipated expansion of Transcode directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Transcode Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Transcode Therapeutics is measured differently than its book value, which is the value of Transcode that is recorded on the company's balance sheet. Investors also form their own opinion of Transcode Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Transcode Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Transcode Therapeutics' market value can be influenced by many factors that don't directly affect Transcode Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Transcode Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Transcode Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Transcode Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Transcode Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Transcode Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Transcode Therapeutics.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Transcode Therapeutics on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Transcode Therapeutics or generate 0.0% return on investment in Transcode Therapeutics over 90 days. Transcode Therapeutics is related to or competes with In8bio, Lyra Therapeutics, Aptevo Therapeutics, Galecto, Phio Pharmaceuticals, HCW Biologics, and Kiora Pharmaceuticals. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and... More
Transcode Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Transcode Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Transcode Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 30.53 | |||
| Value At Risk | (8.21) | |||
| Potential Upside | 8.35 |
Transcode Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Transcode Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Transcode Therapeutics' standard deviation. In reality, there are many statistical measures that can use Transcode Therapeutics historical prices to predict the future Transcode Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | (0.22) |
Transcode Therapeutics January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 4.22 | |||
| Coefficient Of Variation | (1,760) | |||
| Standard Deviation | 6.1 | |||
| Variance | 37.21 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 30.53 | |||
| Value At Risk | (8.21) | |||
| Potential Upside | 8.35 | |||
| Skewness | 1.7 | |||
| Kurtosis | 5.15 |
Transcode Therapeutics Backtested Returns
At this stage we consider Transcode Stock to be moderately volatile. Transcode Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of close to zero, which indicates the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty-four technical indicators for Transcode Therapeutics, which you can use to evaluate the volatility of the company. Please validate Transcode Therapeutics' Variance of 37.21, risk adjusted performance of (0.03), and Coefficient Of Variation of (1,760) to confirm if the risk estimate we provide is consistent with the expected return of 0.0081%. The entity has a beta of 1.59, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Transcode Therapeutics will likely underperform. Transcode Therapeutics right now has a risk of 6.14%. Please validate Transcode Therapeutics maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Transcode Therapeutics will be following its existing price patterns.
Auto-correlation | 0.07 |
Virtually no predictability
Transcode Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Transcode Therapeutics time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Transcode Therapeutics price movement. The serial correlation of 0.07 indicates that barely 7.0% of current Transcode Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.07 | |
| Spearman Rank Test | -0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 2.08 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.